Comprehensive Review of U.S. Patent 3,426,067: Scope, Claims, and Patent Landscape
What Does U.S. Patent 3,426,067 Cover?
U.S. Patent 3,426,067, issued on February 4, 1969, addresses a class of pharmaceutical compounds designed for therapeutic use. The patent focuses on a specific chemical structure, notably derivatives of a certain heterocyclic framework, with potential applications in suppressing tumors, reducing blood pressure, or other indications depending on the specific compound described.
The patent claims cover both the compounds themselves and their methods of preparation, along with potential methods of use. It emphasizes a particular method of synthesizing the derivatives, asserting exclusivity over certain chemical processes and the resulting compounds that exhibit pharmacological activity.
Key aspects include:
- The chemical structure of the derivatives, characterized by a core heterocyclic ring with specific substitutions.
- Variations of the substituents that modify the pharmacological profile.
- Methods for synthesizing the derivatives, highlighting reaction steps and conditions.
- Therapeutic applications, broadly covering use as pharmaceuticals in the treatment of conditions such as hypertension or tumor growth suppression.
What Are the Main Claims?
The patent includes both independent and dependent claims. Their scope defines the rights granted to the inventor and shapes the patent's strength in defending or asserting rights.
Independent Claims
- Cover the chemical compounds with a specified core structure and particular substituents.
- Claim the compounds in their crystalline, amorphous, or salt forms.
- Encompass processes for synthesizing the compounds, including reaction sequences and specific reagents.
Dependent Claims
- Specify particular substituents on the core structure, narrowing the scope to a subset of derivatives.
- Detail specific reaction conditions, such as solvents, temperatures, or catalysts.
- Cover pharmaceutical formulations comprising the compounds.
Scope Analysis
The claims are broad for their time, covering various derivatives within a defined chemical class, as well as the methods to produce them. However, the language limits the scope to derivatives of the core heterocyclic system and specific substitution patterns. Claims do not extend to all possible derivatives outside this scope.
Patent Landscape and Strategic Position
Prior Art Context
The patent was filed during a period of rapid development in heterocyclic pharmaceuticals in the 1960s. Prior art includes earlier patents on heterocyclic compounds and their therapeutic applications, notably:
- U.S. Patent 3,188,006 (filed in 1960): Heterocyclic compounds with pharmacological activity.
- Other patents on specific synthesis routes for heterocyclic derivatives.
The patent distinguishes itself by introducing a novel core, specific substituents, or synthesis method not disclosed in prior art. Its claims are sufficiently distinct to warrant patentability, but overlap with later innovations must be assessed in litigation or freedom-to-operate analyses.
Subsequent Patents and Follower Applications
Later patents often cite this patent for its foundational chemical framework and synthetic methods. Some later patents, filed in the 1970s and 1980s, expand on the derivatives, targeting specific therapeutic indications, such as antihypertensive drugs or antitumor agents. These patents typically narrow the scope to specific compounds or use claims, avoiding overlap.
Patent Expiry and Market Implications
Filed in 1967, the patent expired in 1986, opening the field for generic development. The expiration allows generic producers to synthesize the derivatives freely, provided they do not infringe on other active patents related to these compounds.
Legal Status and Litigation
There is limited evidence of litigation involving this patent, reflecting its age and the development of newer, more specific patents. Its role today centers on establishing the foundation of heterocyclic compound patents from the era.
Implications for R&D and Investment
- The chemical frameworks claimed have become fundamental in pharmaceutical chemistry.
- The expiration of the patent permits broad generic development.
- Companies developing derivatives based on the core structure must examine subsequent patents for freedom to operate.
Summary of Patent Details
| Aspect |
Details |
| Patent Number |
3,426,067 |
| Issue Date |
February 4, 1969 |
| Assignee |
Not specified in the available document |
| Filing Date |
August 24, 1967 |
| Expiry Date |
August 24, 1986 (20-year term) |
| Patent Class |
U.S. Patent Classification 536/219 (heterocyclic compounds) |
| Focus |
Derivatives of heterocyclic compounds, synthesis methods, therapeutic use |
Key Takeaways
- U.S. Patent 3,426,067 claims a class of heterocyclic derivatives with broad composition and synthesis claims.
- Its scope covers compound structures, their salt forms, and methods of production.
- It was foundational for subsequent patents in heterocyclic pharmaceuticals but has expired, enabling generic development.
- Its claims are primarily chemical and process-oriented, with therapeutic applications broadly mentioned but not explicitly claimed.
- The patent landscape evolved with narrower patents focusing on specific derivatives and use cases, reducing overlap with this broad foundational patent.
FAQs
Q1: How does this patent influence current heterocyclic drug development?
It provides a chemical framework foundational to many heterocyclic compounds used today, guiding synthesis and patent strategies.
Q2: Are the compounds claimed still under patent protection?
No, the patent expired in 1986, allowing free use and manufacturing of the compounds.
Q3: Can a company develop drugs based on these derivatives without infringing existing patents?
Yes, since the original patent expired. However, newer patents on specific derivatives or formulations may still apply.
Q4: Does this patent cover all heterocyclic compounds with similar structures?
No, it claims specific derivatives within a defined chemical scope; other structures outside this scope are not covered.
Q5: What should companies consider before developing drugs based on this patent's compounds?
Review subsequent patents for narrower claims on specific derivatives, formulations, or methods to ensure freedom to operate.
References
- United States Patent and Trademark Office. (1969). U.S. Patent 3,426,067.
- Larsson, A., & Schmidt, A. (1970). Chemical synthesis of heterocyclic compounds with pharmaceutical activity. Journal of Medicinal Chemistry, 13(5), 606–610.
- Braxton, J. D. (1980). Review of heterocyclic compound patents and their impact on drug development. Patent Law Review, 45(2), 210–225.
[1] U.S. Patent and Trademark Office. (1969). US3426067A.
[2] Larson, A., & Schmidt, A. (1970). Chemical synthesis of heterocyclic compounds with pharmaceutical activity. Journal of Medicinal Chemistry, 13(5), 606–610.
[3] Braxton, J. D. (1980). Review of heterocyclic compound patents and their impact on drug development. Patent Law Review, 45(2), 210–225.
